VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults
Public ClinicalTrials.gov record NCT03327727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients
Study identification
- NCT ID
- NCT03327727
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Vical
- Industry
- Enrollment
- 4 participants
Conditions and interventions
Interventions
- Investigational Agent: VL-2397 Drug
- Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 19, 2018
- Primary completion
- Jan 13, 2019
- Completion
- Jan 13, 2019
- Last update posted
- Feb 26, 2019
2018 – 2019
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Hospital, Division of Infectious Diseases | Birmingham | Alabama | 35233 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases | Sacramento | California | 95817 | — |
| Christiana Care Health Services, Department of Medicine | Newark | Delaware | 19718 | — |
| Medical College of Georgia at Augusta University | Augusta | Georgia | 30912 | — |
| DMC Harper University Hospital | Detroit | Michigan | 48201 | — |
| University of Minnesota, Department of Medicine | Minneapolis | Minnesota | 55455 | — |
| Washington University School of Medicine, Division of Infectious Disease | St Louis | Missouri | 63110 | — |
| The University of Texas Health Science Center, Department of Internal Medicine | Houston | Texas | 77030 | — |
| Fred Hutchinson Cancer Research Center (FHCRC) | Seattle | Washington | 98109 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03327727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03327727 live on ClinicalTrials.gov.